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Summary
While beta-amyloid (Αβ), anxiety and depression have been linked cross-sectionally to reduced memory function in healthy, non-demented older adults, prospective data evaluating these associations are lacking. Using data from an observational cohort study of 178 healthy, nondemented older adults followed for three years, we found that anxiety symptoms significantly moderated the relation between Αβ level and decline in verbal (Cohen's d=.65) and episodic (Cohen's d=.38) memory. Anxiety symptoms were additionally linked to greater decline in executive function, irrespective of Αβ and other risk factors. These findings suggest that interventions to mitigate anxiety symptoms may help delay memory decline in otherwise healthy older adults with elevated Αβ.
Introduction
Beta-amyloid (Αβ) accumulates incrementally with age and is abnormally elevated in the majority of individuals who meet criteria for mild cognitive impairment (MCI) and Alzheimer's disease (AD) 1 . Abnormal levels of Αβ are also observed in approximately 30% of healthy, nondemented older adults 2 and are associated with clinically significant decline in episodic memory over 18-36 months. 3 Anxiety and depression are also linked to increased Αβ in healthy, nondemented older adults, as well as in adults with MCI and AD, 4, 5 and are known to deleteriously affect episodic memory and related cognitive functions, such as attention and executive function. 6, 7 Taken together, these observations suggest that anxiety and depression may contribute to Αβ-related decline in episodic memory and related cognitive domains in otherwise healthy older adults. However, prospective data evaluating this possibility are lacking. Given that anxiety and depression are amenable to treatment, their identification as determinants or moderators of Αβ-related cognitive decline in healthy older persons is important for managing preclinical and prodromal phases of AD prior to the availability of anti-amyloid therapies.
In this study, we evaluated whether elevated anxiety and depressive symptoms moderated the effect of elevated Αβ on cognitive decline in one of the largest cohorts of healthy, non-demented older adults who have undergone assessment with 11 C-Pittsburgh Compound B (PiB) and whose clinical status was followed prospectively over three years. We hypothesized that elevated anxiety and depressive symptoms at baseline would be associated with increased memory decline over the three-year period of assessment, and that this effect would be independent of traditional risk factors for cognitive decline (e. University. All participants provided written informed consent prior to participating in the study.
PET Imaging and APOE genotyping. Aβ imaging with PET was conducted using 11 C-Pittsburgh
Compound B (PiB). Imaging was conducted over a 30-minute acquisition period that was started 40-70 minutes after the injection of PiB. PET standardized uptake value (SUV) data were summed and normalized to the cerebellar cortex SUV, yielding a region-to-cerebellar ratio termed SUV ratio (SUVR). PiB SUVR levels reflect the mean of Αβ in frontal, post-cingulate, lateral temporal, and occipital cortices. In line with previous studies, SUVR was classified dichotomously as either negative or positive on the basis of SUVR < or ≥ 1.5. An 80ml blood sample was also obtained from each participant, 0.5ml of which was sent to a clinical pathology laboratory for APOE genotyping.
Anxiety and depressive symptoms. Anxiety and depressive symptoms were assessed at the baseline visit using the Hospital Anxiety and Depression Scale (HADS). A total score ≥ 8 on the anxiety and depression items are indicative of clinically elevated anxiety and depressive symptoms, respectively. 
Results
Of the 178 healthy, non-demented older adults who completed a baseline assessment, 163 (91.6%) completed an 18-month follow-up and 138 (77.5%) completed a 36-month follow-up. 
Discussion
Consistent with prior work, 3 results of this study revealed that abnormal levels of Αβ were associated with decline in episodic, verbal, and visual memory in healthy, non-demented older adults. They extend this work by demonstrating that anxiety, but not depressive, symptoms moderated the effect of high Αβ burden on decline in episodic and verbal memory. Specifically, among individuals with abnormal Αβ, those with elevated anxiety symptoms showed a significantly greater decline in episodic and verbal memory over a 3-year study period than those without elevated anxiety symptoms. This additional deleterious effect of anxiety symptoms was, by convention, moderate in magnitude even after statistical adjustment for well-known determinants of cognitive decline, including age, education, IQ, APOE genotype, depressive symptoms, and subjective memory complaints. Anxiety symptoms were unrelated to subjective memory complaints at baseline, which suggests that these symptoms were more general in nature and likely reflective of generalized anxiety symptoms, such as worry, fearfulness, and restlessness. 8 Notably, results of this study did not support our hypothesis, based on extant literature, that anxiety and depressive symptoms at baseline would be associated with increased memory decline over the 3-year study period. Instead, anxiety symptoms predicted overall attention and executive function, and decline in executive function in the full sample; and moderated the association between high Αβ burden and memory decline among healthy, nondemented older adults with elevated Αβ. The low prevalence of depressive symptoms (4.5%) may, at least in part, account for the lack of association between these symptoms and cognitive change; additional research with more clinically diverse samples will be useful in evaluating the direct and moderating effect of depressive symptoms on cognitive change in preclinical AD.
That anxiety symptoms moderated the relation between Αβ level and decline in episodic and verbal memory suggests that this interaction occurs at the level of the hippocampus. Elevated anxiety symptoms may moderate the effect of Αβ on these aspects of memory by increasing endogenous levels of glucocorticoids, which consequently damage the hippocampus and result in more pronounced memory decline over time. 10 Anxiety also diverts and preoccupies prefrontally-mediated attentional resources to fear-and threat-related information, which may in turn negatively affect encoding and retention of verbal information, as well as other prefrontallymediated cognitive processes such as attention and executive function. 7, 10 While this study is limited by the relatively lower proportion of older adults who screened positive for depressive symptoms relative to anxiety symptoms, these results nevertheless suggest that mitigation of elevated anxiety symptoms may help delay episodic and verbal memory decline in healthy, non-demented older adults with elevated Αβ. Of note, because the prevalence of ε4 carriers in the AIBL sample of healthy older adults who underwent neuroimaging was, by design, high (40.7%), additional research in population-based samples of healthy older adults is needed to evaluate the generalizability of these results. Further research is also needed to elucidate neurobiological mechanisms that mediate the relation between Αβ, anxiety symptoms, and cognitive decline; and evaluate the effect of treating elevated anxiety symptoms in mitigating memory decline in normal aging and preclinical AD. 
